After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson’s (NYSE: JNJ) stock price is back in rally mode. It is still early in the game, but the Q2 results affirm that growth is back, acceleration is happening and is expected to continue in the back half of the year.
Acceleration may be stronger than forecasted due to expected approvals and pipeline progress that promise to sustain this company’s growth over the long term. The critical takeaway is that this Dividend King’s capital return is as safe as ever and will continue to grow for the foreseeable future.
